Medical Condition News

RSS

Celtaxsys commences acebilustat phase 2 trial in patients with cystic fibrosis in US

Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from orphan inflammatory diseases, announced today the commencement of the US arm of an international phase 2 clinical trial for its flagship compound, acebilustat, in patients with cystic fibrosis (CF).

8 Oct 2015

Bankers Healthcare Group's company-wide diabetes awareness campaign to run through November

Bankers Healthcare Group, the leading provider of financial solutions for healthcare professionals, recently launched a company-wide diabetes awareness campaign that will run through November.

8 Oct 2015

Up to 1 billion people could be at risk of going blind by 2050, say researchers

Up to 1 billion people could be at risk of blindness by the middle of the century if an emerging short-sightedness (myopia) epidemic is ignored say researchers at the Brien Holden Vision Institute.

8 Oct 2015

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

Salix Pharmaceuticals and Pharming Group NV announced today that the U.S. Food and Drug Administration has granted 12 years of exclusivity to RUCONEST (C1 esterase inhibitor [recombinant]) 50 IU/kg.

8 Oct 2015

SynAgile announces positive results from Phase 2a trial of continuous intraoral LD/CD therapy

SynAgile Corporation, a privately held pharmaceutical company that develops and commercializes drug delivery systems using its proprietary OraFuse intraoral technology platform, today announced positive results from a proof-of-concept, Phase 2a, open-label clinical trial of continuous intraoral administration of levodopa-carbidopa (LD/CD).

8 Oct 2015

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

New results from a Phase II head-to-head psoriasis study showed superior efficacy of Boehringer Ingelheim's investigational biologic compound BI 655066, over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained clear or almost clear skin (PASI 90) with BI 655066 in the higher dose group compared to 30 percent of patients on ustekinumab.

8 Oct 2015

Study assesses customer satisfaction with blood glucose meters

Training materials that are accessible and easy to understand contribute to an overall increase in satisfaction among adults or parents of children with Type 1 or Type 2 diabetes who use a blood glucose meter, and satisfaction is significantly higher when they understand how to use their meter, according to the J.D. Power 2015 U.S. Blood Glucose Meter Satisfaction Study.

8 Oct 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Mallinckrodt plc, a leading specialty biopharmaceutical company, today announced that data from a pilot study for its H.P. Acthar Gel (repository corticotropin injection) will be presented at the American College of Rheumatology 2015 Annual Meeting to be held November 7-11 in San Francisco.

8 Oct 2015

Boston Scientific closes additional financing with MValve Technologies

Boston Scientific Corporation today announced that it has closed on an additional round of financing with MValve Technologies Ltd., a developer of a percutaneous mitral valve replacement system, designed to work with the Boston Scientific LOTUS Valve, creating a unique mitral regurgitation (MR) treatment solution.

8 Oct 2015

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.

8 Oct 2015

Bionomics, Merck extend collaboration to develop drug candidates for treatment of chronic and neuropathic pain

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that it has extended its strategic collaboration with Merck & Co., Inc., Kenilworth NJ., (known as MSD outside the United States and Canada) for the discovery and development of drug candidates for the treatment of chronic and neuropathic pain.

8 Oct 2015

Medtronic unveils next-generation version of superDimension lung navigation system software

Further underscoring its ongoing commitment to lung health, Medtronic today unveiled a next-generation version of its superDimension navigation system software. The superDimension navigation system enables a minimally invasive approach to access difficult-to-reach areas of the lung, and can aid in the diagnosis of lung diseases.

8 Oct 2015

Mental disorders could be underlying risk factors for chronic pain in children and young people

One in four young people have experienced chronic pain and a mental disorder. According to a new report in the Journal of Pain, the onset of pain is often preceded by mental disorders: an above-average rate of incidence of depression, anxiety disorders, and behavioral disorders occurs before the onset of headaches, back pain and neck pain.

8 Oct 2015

Researchers identify completely new information on how cancer cells internally transmit signals

A new study from the University of Turku, Finland, shows that intracellular receptor signalling sustains cancer cells that have detached from the surrounding tissue. When the signalling is prevented, the cells cannot spread to other parts of the body. This significant research result influences how cancer research is directed in the future.

8 Oct 2015

Gut microbiome can play significant role in the body's response to gluten

Investigators interested in celiac disease, a chronic gastrointestinal disorder caused by an immunologic response to the ingestion of gluten, have wondered why only 2% to 5% of genetically susceptible individuals develop the disease.

8 Oct 2015

Controlling TH-containing neurons can manipulate maternal behavior of females and aggression of males

Most female mammals give birth and care for their offspring, while the males often breed with multiple partners and play little role in parenting once the mating is over. Yet researchers have had a hard time pinpointing where, exactly, in the brain these differences between the sexes are located and how they translate into behavior. The extent of "hardwired parental behavior" is hotly disputed.

8 Oct 2015

Study could provide new insight in understanding role of ACC in disorders of social behaviour, empathy

The way our brain responds to others' good fortune is linked to how empathetic people report themselves to be, according to new UCL-led research.

8 Oct 2015

Genentech becomes Founding Sponsor for OPT-UP clinical study in MS, says ACP

Accelerated Cure Project for Multiple Sclerosis (ACP) announced today that Genentech, Inc., a member of the Roche Group, has become a Founding Sponsor for the Optimizing Treatment - Understanding Progression (OPT-UP) clinical study in multiple sclerosis (MS).

8 Oct 2015

Penn study forms basis for new treatment approaches for Sezary syndrome

Sezary syndrome (SS), an aggressive leukemia of mature T cells, is more complicated at a molecular level than ever suspected, according to investigators from the Perelman School of Medicine at the University of Pennsylvania.

8 Oct 2015

Study: Sun exposure during teenage years may delay onset of multiple sclerosis

A study of people with multiple sclerosis (MS) found that those who spent time in the sun every day during the summer as teens developed the disease later than those reporting not spending time in the sun every day.

8 Oct 2015

Medical Condition News

Celtaxsys commences acebilustat phase 2 trial in patients with cystic fibrosis in US

Bankers Healthcare Group's company-wide diabetes awareness campaign to run through November

Up to 1 billion people could be at risk of going blind by 2050, say researchers

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

SynAgile announces positive results from Phase 2a trial of continuous intraoral LD/CD therapy

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

Study assesses customer satisfaction with blood glucose meters

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Boston Scientific closes additional financing with MValve Technologies

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Bionomics, Merck extend collaboration to develop drug candidates for treatment of chronic and neuropathic pain

Medtronic unveils next-generation version of superDimension lung navigation system software

Mental disorders could be underlying risk factors for chronic pain in children and young people

Researchers identify completely new information on how cancer cells internally transmit signals

Gut microbiome can play significant role in the body's response to gluten

Controlling TH-containing neurons can manipulate maternal behavior of females and aggression of males

Study could provide new insight in understanding role of ACC in disorders of social behaviour, empathy

Genentech becomes Founding Sponsor for OPT-UP clinical study in MS, says ACP

Penn study forms basis for new treatment approaches for Sezary syndrome

Study: Sun exposure during teenage years may delay onset of multiple sclerosis

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

A new method to measure intracellular water in biological systems

Obesity, GLP-1s, and metabolic care

Latest News